Addiction & Health

Addiction & Health

An Analysis of Treatment Preferences of Patients With Opioid Use Disorders: Findings From A Tertiary Drug Dependence Treatment Center in India

Document Type : Original Article

Authors
Shalini Singh 1
Newfight Seth 1
Manmeet Kaur Brar 1
Adit Verma 2
Anju Dhawan 1
Siddharth Sarkar 1
1 National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India
2 Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India
10.34172/ahj.1632
Abstract
Background: In this study, we examined the patient preferences for the treatment of opioid use disorders, the factors determining these preferences, and the barriers faced while seeking treatment for opioid use disorders.
Methods: The participants were recruited from both outpatient and inpatient services of a tertiary care centre, and the consenting adults seeking treatment for opioid use disorder were included through purposive sampling. Information on all treatment modalities for opioid use disorders was presented through a video, followed by clarifications. The options included naltrexone (oral, depot, and implant), buprenorphine (sublingual and injection), methadone, tramadol, counselling/psychotherapy, long-term residential treatment, Narcotics Anonymous meetings, and no treatment. Semi-structured questionnaires were used to collect responses, and descriptive statistics were used for data analysis.
Findings: Participants (n = 150) had a median age of 31 years, and were all male. Most (90%) were visiting the treatment centre from other districts, with a median travel time of two hours to reach the centre. Sublingual buprenorphine (41.3%) was the preferred option, followed by oral tramadol (33.3%). The treatment outcomes (77.3%), followed by logistic reasons (14.7%), were the major determining factors for choosing a treatment option. Frequent dispensing schedules (54%) and unavailability of medication near their residence (25.3%) were the major barriers to seeking long-term care.
Conclusion: There was a greater preference for oral opioid agonist medication over all other formulations. A wider availability of medications for opioid agonist maintenance treatment could improve treatment-seeking rates. Further research on treatment preference could include diverse patient groups, caregivers, and treatment providers.

Highlights

Siddharth Sarkar(Google Scholar)(PubMed)

Keywords
Opioid-related disorders
Patient preference
Treatment outcome
Long-term care
Buprenorphine
  1. Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N, et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction 2014;109(8):1320-33. doi: 10.1111/ add.12551
  2. Sarkar S, Balhara YP, Gautam N, Singh J. A retrospective chart review of treatment completers versus noncompleters among in-patients at a tertiary care drug dependence treatment centre in India. Indian J Psychol Med 2016;38(4):296-301. doi: 10.4103/0253-7176.185943
  3. Koehl JL, Zimmerman DE, Bridgeman PJ. Medications for management of opioid use disorder. Am J Health Syst Pharm 2019;76(15):1097-103. doi: 10.1093/ajhp/zxz105
  4. Adriana NP, Wicaksono D. Alcoholic/narcotic anonymous program outcome: a systematic review. Indones J Med 2023;8(3):331-8. doi: 10.26911/theijmed.2023.08.03.11
  5. Friedrichs A, Spies M, Härter M, Buchholz A. Patient preferences and shared decision making in the treatment of substance use disorders: a systematic review of the literature. PLoS One 2016;11(1):e0145817. doi: 10.1371/journal. pone.0145817
  6. Kenney SR, Anderson BJ, Bailey GL, Stein MD. Buprenorphine treatment formulations: preferences among persons in opioid withdrawal management. J Subst Abuse Treat 2018;94:55-9. doi: 10.1016/j.jsat.2018.08.011
  7. Zaaijer ER, Goudriaan AE, Koeter MW, Booij J, van den Brink W. Acceptability of extended-release naltrexone by heroin-dependent patients and addiction treatment providers in the Netherlands. Subst Use Misuse 2016;51(14):1905-11. doi: 10.1080/10826084.2016.1201117
  8. Saunders EC, Moore SK, Walsh O, Metcalf SA, Budney AJ, Scherer E, et al. Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders. J Subst Abuse Treat 2020;111:54-66. doi: 10.1016/j.jsat.2020.01.009
  9. Chappuy M, Meroueh F, Trojak B, Bachellier J, Bendimerad P, Kosim M, et al. Factors of interest in extended-release buprenorphine: comparisons between incarcerated and non-incarcerated patients with opioid use disorder. Patient Prefer Adherence 2021;15:1259-67. doi: 10.2147/ppa.S311674
  10. Dhawan A, Chopra A, Ray R. Preferences for treatment setting by substance users in India. Indian J Psychol Med 2016;38(1):42-5. doi: 10.4103/0253-7176.175105
  11. Chatterjee A, Strong G, Meinert E, Milne-Ives M, Halkes M, Wyatt-Haines E. The use of video for patient information and education: a scoping review of the variability and effectiveness of interventions. Patient Educ Couns 2021;104(9):2189-99. doi: 10.1016/j.pec.2021.02.009
  12. Sarkar S, Varshney M, Patil V, Lal R. Maintainence treatment of opioid dependence with tramadol. J Neurosci Rural Pract 2017;8(Suppl 1):S98-101. doi: 10.4103/jnrp.jnrp_422_16
  13. Ambekar A, Rao R, Agrawal A, Kathiresan P. Research on opioid substitution therapy in India: a brief, narrative review. Indian J Psychiatry. 2018;60(3):265-70. doi: 10.4103/ psychiatry.IndianJPsychiatry_385_18
  14. Cioe K, Biondi BE, Easly R, Simard A, Zheng X, Springer SA. A systematic review of patients’ and providers’ perspectives of medications for treatment of opioid use disorder. J Subst Abuse Treat 2020;119:108146. doi: 10.1016/j.jsat.2020.108146
  15. Peterson JA, Schwartz RP, Mitchell SG, Reisinger HS, Kelly SM, O’Grady KE, et al. Why don’t out-of-treatment individuals enter methadone treatment programmes? Int J Drug Policy 2010;21(1):36-42. doi: 10.1016/j.drugpo.2008.07.004
  16. Wu F, Peng CY, Jiang H, Zhang R, Zhao M, Li J, et al. Methadone maintenance treatment in China: perceived challenges from the perspectives of service providers and patients. J Public Health (Oxf) 2013;35(2):206-12. doi: 10.1093/pubmed/ fds079
  17. Rozanova J, Marcus R, Taxman FS, Bojko MJ, Madden L, Farnum SO, et al. Why people who inject drugs voluntarily transition off methadone in Ukraine. Qual Health Res 2017;27(13):2057-70. doi: 10.1177/1049732317732307
  18. Amini-Rarani M, Moeeni M, Ponnet K. Male patients’ preferences for opioid use treatment programs. BMC Psychiatry 2023;23(1):440. doi: 10.1186/s12888-023-04939-x 
  19. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010;375(9719):1014- 28. doi: 10.1016/s0140-6736(10)60232-2 
  20. Ambekar A, Murthy P, Basu D, Rao GP, Mohan A. Challenges in the scale-up of opioid substitution treatment in India. Indian J Psychiatry 2017;59(1):6-9. doi: 10.4103/psychiatry. IndianJPsychiatry_14_17 
  21. Hayes BT, Jakubowski A, Fitzsimmons C, Garcia B, Ramirez F, Fox AD. “The doctor says you cannot have [buprenorphine]” autonomy and use of prescribed or non-prescribed buprenorphine. Subst Use Misuse 2021;56(8):1137-43. doi: 10.1080/10826084.2021.1908360 
  22. Lachapelle É, Archambault L, Blouin C, Perreault M. Perspectives of people with opioid use disorder on improving addiction treatments and services. Drugs (Abingdon Engl) 2021;28(4):316-27. doi: 10.1080/09687637.2020.1833837 
  23. Tompkins CNE, Neale J, Strang J. Opioid users’ willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder. J Subst Abuse Treat 2019;104:64-71. doi: 10.1016/j.jsat.2019.06.007 
  24. Uebelacker LA, Bailey G, Herman D, Anderson B, Stein M. Patients’ beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. J Subst Abuse Treat 2016;66:48-53. doi: 10.1016/j.jsat.2016.02.009 
  25. Perez-Macia V, Martinez-Cortes M, Mesones J, Segura- Trepichio M, Garcia-Fernandez L. Monitoring and improving naltrexone adherence in patients with substance use disorder. Patient Prefer Adherence 2021;15:999-1015. doi: 10.2147/ ppa.S277861
Addiction & Health
Volume 18
Pages 1-7